Cellply

🎉 Exciting News! We’re thrilled to announce that Cellply will be an exhibitor at #ICLE2025! 🎉 But that’s not all - our colleague Paola Poggi will also be presenting in the poster session, where we’ll introduce a 𝗴𝗿𝗼𝘂𝗻𝗱𝗯𝗿𝗲𝗮𝗸𝗶𝗻𝗴 𝗶𝗻𝗻𝗼𝘃𝗮𝘁𝗶𝗼𝗻 𝗶𝗻 𝗰𝘆𝘁𝗼𝗸𝗶𝗻𝗲 𝗱𝗲𝘁𝗲𝗰𝘁𝗶𝗼𝗻. 🔬 Our study highlights a cutting-edge microfluidic-based assay designed for the detection and quantification of cytokines from co-culture supernatants. By leveraging a commercially available microbeads system, this automated approach brings significant advantages: ✅ Improved reproducibility ✅ Reduced hands-on time ✅ Minimal sample volume requirements Don’t miss this opportunity to meet us at the event! 📍𝗕𝗼𝗼𝘁𝗵 #𝟰 📜 𝗣𝗼𝘀𝘁𝗲𝗿 #𝟭𝟭𝟮 #ICLE2025 #CellTherapy #Cytokine

Today, 5 pm to 8 pm PT! #JPM25 #CellTherapy #AdvancedTherapies

🚀𝗖𝗲𝗹𝗹𝗽𝗹𝘆 𝗶𝘀 𝗵𝗲𝗮𝗱𝗶𝗻𝗴 𝘁𝗼 𝗦𝗮𝗻 𝗙𝗿𝗮𝗻𝗰𝗶𝘀𝗰𝗼! Our founder and Chief Strategy Officer Massimo Bocchi will take part to the 43rd edition of the J.P. Morgan Conference, taking place on 13-16 January 2025 in San Francisco. We are also proud to announce that Cellply has been selected to present at the #𝗜𝘁𝗮𝗹𝘆𝗢𝗻𝗧𝗵𝗲𝗠𝗼𝘃𝗲 pitch event taking place on January 15th at 5pm at the INNOVIT - Italian Innovation and Culture Hub and organized by ITA - Italian Trade Agency, the Consulate General of Italy in San Francisco, La Farnesina Ministero degli Affari Esteri, the Ministero delle Imprese e del Made in Italy, Invitalia, and Invest in Italy. ➡️ Reach out to Massimo Bocchi if you are interested in scheduling a meeting in San Francisco to know more about Cellply and how our VivaCyte platform characterize cell therapies with an unprecedented level of automation and depth. #JPM25 #CellTherapy #AdvancedTherapies

Thanks to our collaboration with Festo Italia, we have made the layout of our VivaCyte® platform more efficient in terms of both space utilization and automation. #Partnership #Automation #CellTherapy

⏳ Don't miss the opportunity to join our Webinar with Silvia Bocchi, Assay Development Leader. Hear how Workflow 2 on VivaCyte is providing the scientific community with a 𝗽𝗼𝘄𝗲𝗿𝗳𝘂𝗹 𝗻𝗲𝘄 𝗽𝗼𝘁𝗲𝗻𝗰𝘆 𝗮𝘀𝘀𝗲𝘀𝘀𝗺𝗲𝗻𝘁 𝘁𝗼𝗼𝗹 𝘁𝗵𝗮𝘁 𝗲𝗻𝗮𝗯𝗹𝗲𝘀 𝗺𝗼𝗿𝗲 𝗿𝗼𝗯𝘂𝘀𝘁 𝗮𝗻𝗮𝗹𝘆𝘀𝗶𝘀 𝘄𝗶𝘁𝗵 𝗳𝗲𝘄𝗲𝗿 𝗿𝗲𝘀𝗼𝘂𝗿𝗰𝗲𝘀. 🎤 Speaker: Silvia Bocchi, Assay Development Leader at Cellply 📅 Date: December, 3 📍 Hosted by: Cellply 👉 Register now! 𝗘𝗨𝗥𝗢𝗣𝗘𝗔𝗡 𝗦𝗘𝗦𝗦𝗜𝗢𝗡: 🕑 2.00 pm CET https://lnkd.in/dHBNNHXS 𝗨𝗦 𝗦𝗘𝗦𝗦𝗜𝗢𝗡:  🕘 9.00 am PST https://lnkd.in/dg-vHysG #Webinar #CellTherapy #ImmuneCell #Biotech

Join our webinar and discover a powerful new single-cell level high throughput potency analysis method based on an immune cell killing assay. 🎤 Speaker: Silvia Bocchi, Assay Development Leader at Cellply 📅 Date: December, 3 📍 Hosted by: Cellply Our Workflow 2, officially launched at #SITC2024 in Houston, can provide the scientific community with a powerful new potency assessment tool that enables more robust analysis with fewer resources. 👉 Register now! 𝗘𝗨𝗥𝗢𝗣𝗘𝗔𝗡 𝗦𝗘𝗦𝗦𝗜𝗢𝗡: 🕑 2.00 pm CET https://lnkd.in/dHBNNHXS 𝗨𝗦 𝗦𝗘𝗦𝗦𝗜𝗢𝗡:  🕘 9.00 am PST https://lnkd.in/dg-vHysG #Webinar #CellTherapy #ImmuneCell #Biotech

𝑾𝒉𝒂𝒕 𝒊𝒎𝒑𝒂𝒄𝒕 𝒅𝒐𝒆𝒔 𝒕𝒉𝒆 𝒎𝒂𝒏𝒖𝒇𝒂𝒄𝒕𝒖𝒓𝒊𝒏𝒈 𝒑𝒓𝒐𝒄𝒆𝒔𝒔 𝒄𝒖𝒓𝒓𝒆𝒏𝒕𝒍𝒚 𝒉𝒂𝒗𝒆 𝒐𝒏 𝑨𝒅𝒗𝒂𝒏𝒄𝒆𝒅 𝑻𝒉𝒆𝒓𝒂𝒑𝒊𝒆𝒔 𝒑𝒓𝒐𝒅𝒖𝒄𝒕𝒔? 🧬 🏭 What aspects of manufacturing and quality control can we improve so that these products are licensable by regulatory agencies, ensuring not only efficacy, but also easy access and sustainability? We were pleased to contribute to the first stage of the OTA Talk organised by Osservatorio Terapie Avanzate and held in Rome on November 18. A format that aims to open the dialogue between key players in the world of TA and regulators. #AdvancedTherapies #CellTherapy

🎉 We are honored to have been selected as one of the winners in the Health category. A huge thank you to EIC Scaling Club, mentors, and stakeholders for fostering such an inspiring and collaborative environment. #EICScalingClub #EUeic #Biotech #HealthTech

ICYMI we chose #SITC2024 to introduce Workflow 2 - a novel immune-cell killing assay for suspension cells using VivaCyte. 𝐖𝐅𝟐 𝐩𝐫𝐨𝐯𝐢𝐝𝐞𝐬 𝐫𝐚𝐩𝐢𝐝 𝐝𝐨𝐬𝐞-𝐫𝐞𝐬𝐩𝐨𝐧𝐬𝐞 𝐛𝐚𝐬𝐞𝐝 𝐚𝐧𝐚𝐥𝐲𝐬𝐢𝐬 – 𝐦𝐚𝐝𝐞 𝐩𝐨𝐬𝐬𝐢𝐛𝐥𝐞 𝐛𝐲 𝐭𝐡𝐞 𝐚𝐮𝐭𝐨𝐦𝐚𝐭𝐞𝐝 𝐜𝐫𝐞𝐚𝐭𝐢𝐨𝐧 𝐨𝐟 𝐭𝐡𝐨𝐮𝐬𝐚𝐧𝐝𝐬 𝐨𝐟 𝐦𝐢𝐧𝐢𝐚𝐭𝐮𝐫𝐢𝐳𝐞𝐝 𝐜𝐨-𝐜𝐮𝐥𝐭𝐮𝐫𝐞𝐬 𝐨𝐟 𝐯𝐚𝐫𝐲𝐢𝐧𝐠 𝐄:𝐓 𝐫𝐚𝐭𝐢𝐨𝐬. AI-powered image analysis means multiple cell therapy samples are automatically analysed and compared - this new characterization tool saves time, effort and precious sample. Immune cell therapy researchers and process development experts can now push the boundaries of what’s possible in lead identification and batch comparison characterization. Silvia Bocchi, of our scientific team, presented poster #125 - "New high throughput parallel screening technique for automatic creation of Dose-Response analysis with multiple E:T ratios, using minimal sample." Contact Massimo Bocchi to get a copy of the validation poster and discuss how this miniaturized immune cell killing assay on VivaCyte is shaping the immunotherapy characterization landscape. #SITC2024 #CellTherapy #CancerResearch

Cellply scientific team are proud to be presenting poster #125 at #SITC2024  Entitled, "𝑵𝒆𝒘 𝒉𝒊𝒈𝒉 𝒕𝒉𝒓𝒐𝒖𝒈𝒉𝒑𝒖𝒕 𝒑𝒂𝒓𝒂𝒍𝒍𝒆𝒍 𝒔𝒄𝒓𝒆𝒆𝒏𝒊𝒏𝒈 𝒕𝒆𝒄𝒉𝒏𝒊𝒒𝒖𝒆 𝒇𝒐𝒓 𝒂𝒖𝒕𝒐𝒎𝒂𝒕𝒊𝒄 𝒄𝒓𝒆𝒂𝒕𝒊𝒐𝒏 𝒐𝒇 𝑫𝒐𝒔𝒆-𝑹𝒆𝒔𝒑𝒐𝒏𝒔𝒆 𝒂𝒏𝒂𝒍𝒚𝒔𝒊𝒔 𝒘𝒊𝒕𝒉 𝒎𝒖𝒍𝒕𝒊𝒑𝒍𝒆 𝑬:𝑻 𝒓𝒂𝒕𝒊𝒐𝒔, 𝒖𝒔𝒊𝒏𝒈 𝒎𝒊𝒏𝒊𝒎𝒂𝒍 𝒔𝒂𝒎𝒑𝒍𝒆." Join us on Friday, Nov. 8 for a closer look at how this miniaturized immune cell killing assay on VivaCyte is shaping the immunotherapy characterization landscape. Unable to attend #SITC2024 this year? Contact Massimo Bocchi to get a copy of this poster! #SITC2024 #CellTherapy #CancerResearch